The Urocross Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is intentionally retrieved, leaving no permanent foreign material behind.
Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...
Image courtesy of Prodeon Medical] Prodeon Medical announced today that it received FDA 510(k) clearance for its Urocross ...
Medical Device Network on MSN
Prodeon Medical’s BPH implant gains FDA clearance
In data supporting FDA approval, 48.1% implanted with Prodeon’s Urocross saw International Prostate Symptom Score improvements.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results